Bristol-Myers Squibb
Official SEC filings
Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 10:43 UTC.
| Form | Filed | Original document |
|---|---|---|
| 10-Q | 2026-10-29 | Read on SEC.gov |
| 8-K | 2026-10-29 | Read on SEC.gov |
| 10-Q | 2026-07-30 | Read on SEC.gov |
| 8-K | 2026-07-30 | Read on SEC.gov |
| 8-K | 2026-05-08 | Read on SEC.gov |
| 10-Q | 2026-04-30 | Read on SEC.gov |
| 8-K | 2026-04-30 | Read on SEC.gov |
| 10-K | 2026-02-11 | Read on SEC.gov |
SEC annual financial snapshot
Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-22 05:51 UTC.
| Metric | USD | Basis | Period end | Filed | Source |
|---|---|---|---|---|---|
| Revenue | $48.19B | Annual | 2025-12-31 | 2026-02-11 | 10-K |
| Net income | $7.05B | Annual | 2025-12-31 | 2026-02-11 | 10-K |
| Operating cash flow | $14.16B | Annual | 2025-12-31 | 2026-02-11 | 10-K |
| Total assets | $90.04B | As of | 2025-12-31 | 2026-02-11 | 10-K |
| Total liabilities | $71.53B | As of | 2025-12-31 | 2026-02-11 | 10-K |
| Stockholders’ equity | $18.47B | As of | 2025-12-31 | 2026-02-11 | 10-K |
| Cash and cash equivalents | $10.21B | As of | 2025-12-31 | 2026-02-11 | 10-K |
✦ Quant Financial Health how this is computed
- Altman Z-Score is 2.39, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
✦ Quant Revenue Concentration how this is computed
- Eliquis is the largest reported line at 35.89% of revenue, across 10 reported segments.
- No single line clears half of revenue; Opdivo is next at 18.17%, spreading the business across more than one real driver.
Revenue annual, last 8 years
Latest year -0.22% YoY
Margins
- Gross margin
- 71.08%
- Operating margin
- 28.48%
- Net margin
- 14.64%
Key ratios & quality
- Enterprise valuei
- 154.83B
- PEG ratioi
- 3.53
- Altman Z-Scorei
- 2.39
PEG uses trailing P/E against the 3-year net income growth rate (3.69%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.56B | 26.15B | 42.52B | 46.39B | 46.16B | 45.01B | 48.30B | 48.19B |
| Gross profit | 16.09B | 18.07B | 30.75B | 36.45B | 36.02B | 34.31B | 34.33B | 34.26B |
| Selling & admin expenses | 4.52B | 6.47B | 7.65B | 7.69B | 7.81B | 7.77B | 8.41B | 7.27B |
| Research & development | 6.33B | 6.15B | 11.14B | 10.20B | 9.51B | 9.30B | 11.16B | 9.95B |
| Operating profit | 5.14B | 4.31B | 2.19B | 8.54B | 9.10B | 8.20B | 5.89B | 13.72B |
| Pretax profit | 5.97B | 4.98B | -6.87B | 8.10B | 7.71B | 8.44B | -8.38B | 9.33B |
| Tax | 1.02B | 1.52B | 2.12B | 1.08B | 1.37B | 400.00M | 554.00M | 2.27B |
| Net profit | 4.95B | 3.46B | -9.00B | 7.01B | 6.35B | 8.04B | -8.93B | 7.06B |
| Basic EPS | 3 | 2 | -4 | 3 | 3 | 4 | -4 | 3 |
| Diluted EPS | 3.01 | 2.01 | -3.99 | 3.12 | 2.95 | 3.86 | -4.41 | 3.46 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 12.27B | 12.22B | 12.50B | 11.49B | 12.97B | 13.07B |
| Gross profit | 8.90B | 8.79B | 8.41B | 8.07B | 9.25B | 8.92B |
| Selling & admin expenses | 1.71B | 1.79B | 2.18B | 1.62B | 1.83B | 1.70B |
| Research & development | 2.58B | 2.53B | 2.59B | 2.65B | 2.96B | 2.37B |
| Operating profit | 3.77B | 3.64B | 2.81B | 3.37B | 4.03B | 4.40B |
| Pretax profit | 1.77B | 3.11B | 1.47B | 3.24B | 4.09B | 2.54B |
| Tax | 460.00M | 919.00M | 384.00M | 561.00M | 770.00M | 374.00M |
| Net profit | 1.31B | 2.20B | 1.09B | 2.68B | 3.32B | 2.16B |
| Basic EPS | 1 | 1 | 1 | 1 | 2 | 1 |
| Diluted EPS | 0.64 | 1.08 | 0.53 | 1.31 | 1.62 | 1.05 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 17.72B | 29.35B | 30.19B | 33.26B | 27.27B | 31.77B | 29.78B | 29.39B |
| Cash & ST investments | 8.76B | 15.39B | 16.45B | 17.22B | 9.25B | 12.28B | 10.86B | 10.67B |
| Inventory | 1.20B | 4.29B | 2.07B | 2.10B | 2.34B | 2.66B | 2.56B | 2.69B |
| Total assets | 34.99B | 129.94B | 118.48B | 109.31B | 96.82B | 95.16B | 92.60B | 90.04B |
| Total current liabilities | 10.65B | 18.30B | 19.08B | 21.87B | 21.89B | 22.26B | 23.77B | 23.42B |
| Short-term debt | 1.70B | 3.48B | 2.50B | 5.12B | 4.40B | 3.28B | 2.23B | 2.46B |
| Long-term debt | 5.65B | 43.39B | 48.34B | 39.61B | 35.06B | 36.65B | 47.60B | 42.85B |
| Total liabilities | 20,859,000,000.00 | 78,246,000,000.00 | 80,599,000,000.00 | 73,308,000,000.00 | 65,702,000,000.00 | 65,674,000,000.00 | 76,215,000,000.00 | 71,532,000,000.00 |
| Total equity | 14.13B | 51.70B | 37.88B | 36.01B | 31.12B | 29.49B | 16.39B | 18.51B |
| Retained earnings | 34.07B | 34.47B | 21.28B | 23.82B | 25.50B | 28.77B | 14.91B | 16.90B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 33.22B | 35.63B | 29.39B | 27.21B | 28.58B | 29.77B |
| Cash & ST investments | 13.60B | 16.50B | 10.67B | 10.49B | 11.07B | 12.58B |
| Inventory | 2.74B | 2.76B | 2.69B | 2.76B | 2.74B | 2.70B |
| Total assets | 94.68B | 96.89B | 90.04B | 86.48B | 87.63B | 88.77B |
| Total current liabilities | 27.53B | 28.14B | 23.42B | 19.16B | 18.66B | 18.75B |
| Short-term debt | 4.91B | 4.72B | 2.46B | 2.51B | 1.23B | 1.25B |
| Long-term debt | 44.47B | 44.47B | 42.85B | 42.15B | 42.09B | 41.85B |
| Total liabilities | 77,187,000,000.00 | 78,289,000,000.00 | 71,532,000,000.00 | 66,374,000,000.00 | 65,315,000,000.00 | 65,368,000,000.00 |
| Total equity | 17.49B | 18.60B | 18.51B | 20.10B | 22.32B | 23.40B |
| Retained earnings | 16.15B | 17.09B | 16.90B | 18.29B | 20.32B | 21.19B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 7.07B | 8.21B | 14.05B | 16.21B | 13.07B | 13.86B | 15.19B | 14.16B |
| Depreciation & amortization | 637.00M | 1.75B | 10.38B | 10.69B | 10.28B | 9.76B | 9.60B | 4.01B |
| Free cash flow | 6.12B | 7.37B | 13.30B | 15.23B | 11.95B | 12.65B | 13.94B | 12.85B |
| Dividends paid | -2.61B | -2.68B | -4.08B | -4.40B | -4.63B | -4.74B | -4.86B | -5.05B |
| Stock buybacks / issuance | -320.00M | -7.30B | -1.55B | -6.29B | -8.00B | -5.16B | 0 | 0 |
| Ending cash balance | 6.91B | 12.82B | 14.97B | 14.32B | 9.33B | 11.52B | 10.35B | 10.22B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 3.92B | 6.31B | 1.97B | 1.10B | 3.39B | 4.18B |
| Depreciation & amortization | 1.01B | 1.01B | 977.00M | 594.00M | 594.00M | 626.00M |
| Free cash flow | 3.56B | 5.99B | 1.60B | 757.00M | 3.09B | 3.84B |
| Dividends paid | -1.26B | -1.26B | -1.26B | -1.28B | -1.29B | -1.29B |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 12.61B | 15.73B | 10.22B | 9.58B | 8.72B | 9.57B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 38.18 | 10.48 | -20.16 | 18.96 | 18.88 | 26.53 | -39.10 | 40.53 |
| ROA %i | 14.36 | 4.17 | -7.26 | 6.14 | 6.14 | 8.36 | -9.53 | 7.72 |
| ROIC %i | 24.69 | 6.46 | -8.46 | 9.53 | 9.58 | 12.81 | -10.84 | 12.74 |
| 5-year avg ROE %i | 19.76 | 19.18 | 13.00 | 10.93 | 13.27 | 10.94 | 1.02 | 13.16 |
| EBIT margin %i | 27.26 | 21.54 | -12.82 | 20.33 | 19.38 | 21.34 | -13.32 | 23.28 |
| FCF / sales %i | 22.11 | 27.66 | 31.28 | 32.84 | 25.88 | 28.11 | 28.87 | 26.65 |
| Current ratioi | 1.66 | 1.60 | 1.58 | 1.52 | 1.25 | 1.43 | 1.25 | 1.26 |
| Quick ratioi | 1.36 | 1.26 | 1.42 | 1.36 | 1.06 | 1.24 | 1.06 | 1.08 |
| Debt / assetsi | 21.01 | 36.58 | 43.61 | 41.71 | 42.05 | 43.57 | 55.29 | 52.35 |
| LT debt / equityi | 40.24 | 85.39 | 130.00 | 112.61 | 116.92 | 129.74 | 299.80 | 241.84 |
| Interest coveragei | 33.61 | 8.58 | -3.84 | 7.07 | 7.26 | 8.24 | -3.30 | 5.93 |
| Revenue CAGR (3Y) %i | 10.86 | 10.41 | 26.96 | 27.16 | 20.86 | 1.91 | 1.36 | 1.45 |
| Net income CAGR (3Y) %i | 46.49 | -8.28 | -- | 12.44 | 22.53 | -- | -- | 3.69 |
| FCF CAGR (3Y) %i | 68.20 | 58.75 | 46.61 | 35.56 | 17.45 | -1.65 | -2.91 | 2.44 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | 29.31 | 33.84 | 40.53 | 38.84 | 46.70 | 44.06 |
| ROA %i | 5.33 | 6.34 | 7.72 | 8.13 | 10.18 | 9.96 |
| ROIC %i | 9.43 | 10.87 | 12.74 | 12.80 | 15.66 | 15.37 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 17.98 | 20.79 | 23.28 | 23.52 | 27.73 | 25.95 |
| FCF / sales %i | 30.56 | 31.86 | 26.65 | 24.56 | 23.26 | 18.56 |
| Current ratioi | 1.21 | 1.27 | 1.26 | 1.42 | 1.53 | 1.59 |
| Quick ratioi | 1.04 | 1.11 | 1.08 | 1.18 | 1.29 | 1.36 |
| Debt / assetsi | 53.79 | 52.68 | 52.35 | 53.69 | 51.41 | 50.48 |
| LT debt / equityi | 263.95 | 249.67 | 241.84 | 218.87 | 196.33 | 186.13 |
| Interest coveragei | 4.33 | 5.11 | 5.93 | 6.31 | 7.88 | 7.86 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.
Bristol-Myers Squibb discussion 0 comments